- Home
- KTF vs STRO Comparison
KTF vs STRO Comparison
Compare KTF & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KTF | STRO |
|---|---|---|
| Founded | 1988 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 361.2M | 332.8M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | KTF | STRO |
|---|---|---|
| Price | $8.40 | $16.56 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $31.33 |
| AVG Volume (30 Days) | 162.2K | ★ 207.3K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 3.54% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.39 | N/A |
| Revenue | N/A | ★ $38,419,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $21.69 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.45 | $0.72 |
| 52 Week High | $9.37 | $43.85 |
Technical Indicators
Market Signals| Indicator | KTF | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 17.50 | 25.59 |
| Support Level | N/A | $10.34 |
| Resistance Level | $9.25 | $17.33 |
| Average True Range (ATR) | 0.06 | 1.03 |
| MACD | -0.03 | -0.25 |
| Stochastic Oscillator | 2.33 | 8.04 |
Price Performance
Historical ComparisonAbout KTF DWS Municipal Income Trust
DWS Municipal Income Trust is a closed-ended fixed income mutual fund launched and managed by Deutsche Investment Management Americas, Inc. The company invests in the fixed income markets of the United States. The fund invests in investment-grade tax-exempt municipal securities which are exempt from federal income tax. The fund benchmarks the performance of its portfolio against the Barclays Municipal Bond Index. The Fund invests in various states, such as Texas, Florida, Pennsylvania, Illinois, and California.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.